Asia-Pacific Continuous Bioprocessing Market (2025-2032)
The Asia-Pacific Continuous Bioprocessing Market is expected to grow at a CAGR of 28.9% from 2025 to 2032 to reach $181.1 million by 2032.
- Published
- Jan 2025
- Pages
- 145
- Format
- PDF + Excel
- Report ID
- MRHC - 104999
- Base year
- 2024
- 2032 · FORECAST
- $181.1M
- 2032
- $181.1M
- CAGR 2025–2032
- 28.9%
2024 baseline · 2025–2032 forecast at 28.9% CAGR · hover a bar for the value
Key highlights
The Asia-Pacific Continuous Bioprocessing Market is expected to grow at a CAGR of 28.9% from 2025 to 2032 to reach $181.1 million by 2032.
The Commercial Application Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
In 2025, China is estimated to dominate the Asia-Pacific continuous bioprocessing market. Though China has the largest adoption, China’s biopharma sector faces multiple challenges in quality management, including a lack of experience and talent, a rapidly changing regulatory environment, as well as cultural issues in management.
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 181.1 million |
| CAGR (2025–2032) | 28.9% |
| Format | PDF, Excel & Cloud Portal · 145 pages |
| Segments Covered | By Product: Filtration Systems and Consumables, Chromatography Systems and Consumables, Cell Culture Media, Buffers, and Reagents, Incubators and Shakers, Bioreactors, Centrifuges, Sterilizers, Other Instruments and Consumables · By Application: Commercial Applications Monoclonal Antibodies (MAB) Production, Cell and Gene Therapy Production, Vaccine Manufacturing, Plasma Fractionation, Recombinant Protein Production · By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes |
| Countries Covered | Asia-Pacific (RoE) |
| Key Companies | Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Repligen Corporation, Eppendorf AG, Pall Corporation, Electrolab Biotech Limited |
Report overview
Segments covered: product, application, end user. Regions: Asia-Pacific.
Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition. Continuous bioprocessing is increasingly being adopted due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, utilizing compact facilities and equipment, and enhancing product quality to facilitate real-time release.
The growth of the continuous bioprocessing market in Asia-Pacific is attributed to the gradual adoption of continuous manufacturing, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.
However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.
The current push of biotech R&D towards establishing a biotherapeutic landscape and improving the regulatory landscape for the development and approval of biosimilars supported companies to expand biopharma capacity:
In December 2020, Alvotech (Iceland) and Fuji Pharma, a Japanese pharmaceutical company, extended their partnership to commercialize four biosimilars in Japan.
In December 2020, RoosterBio, Inc., a South Korean supplier of cellular therapy bioprocess tools, entered into an agreement with Sartorius Korea Biotechto launch RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia.
In October 2020, the company announced raising funding from private equity investors for investments in biologics. In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
Companies like Biocon Ltd. (India) are developing strategies to expand their R&D base in India. In September 2019, Biocon acquired Pfizer Healthcare (U.S.) assets to set up a second R&D facility in India to boost biosimilars development.
In June 2018, Lupin Limited (India) partnered with Nichi-Iko Pharmaceutical Co., Ltd., to launch biosimilars in the Japanese market.
The demand for innovative manufacturing methods like continuous processing is rising due to the increasing R&D and bioproduction. For instance,
In January 2021, Biocon announced an investment of USD 75 million for Biocon Biologics to boost biosimilar development in India.
In November 2020, South Korea-based Celltrion announced an investment of USD 453 million for building a third manufacturing and R&D site in South Korea.
In August 2020, one of the leading CDMOs in Japan, Bushu Pharmaceuticals Ltd., announced a major expansion program with an investment of USD 100 million to expand capacity and portfolio.
Report infographic
Table of contents
11 chapters · 161 sections · 145 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| Other segments | Commercial Application | — |
Other segments
- The Commercial Application Segment is Expected to Account for the Largest Share of the Asia-Pacific Continuous Bioprocessing Market
- The commercial applications segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market.
- Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, growing investments in constructing facilities compatible with continuous bioprocessing for the commercial manufacture of biopharmaceuticals, and accelerated developments in personalized therapies drive the adoption of continuous bioprocessing for commercial application.
- The Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of Asia-Pacific Continuous Bioprocessing Market
- The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the Asia-Pacific continuous bioprocessing market.
- The large share of this segment is attributed to factors such as the transition of pharma and biopharma manufacturers from batch to continuous processing, regulatory authorities' increasing emphasis on continuous bioprocessing, and the rising investments directed toward the integration of continuous processing technologies.
Geographic analysis
Asia-Pacific
Largest shareIn 2025, China is estimated to dominate the Asia-Pacific continuous bioprocessing market. Though China has the largest adoption, China’s biopharma sector faces multiple challenges in quality management, including a lack of experience and talent, a rapidly changing regulatory environment, as well as cultural issues in management. These factors are projected to hinder the growth of this market to a certain extent. China to Account for the Largest Market Share in 2025
Competitive landscape
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Sartorius AG
- Repligen Corporation
- Eppendorf AG
- Pall Corporation
- Electrolab Biotech Limited
Frequently asked questions
This report covers the market sizes & forecasts for various products, applications, end user, and geography. It also involves the value analysis of various segments and sub-segments of continuous bioprocessing at the country level.
Cite this report
Meticulous Research. (2025). Asia-Pacific Continuous Bioprocessing Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 104999). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-continuous-bioprocessing-market-5682